We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look at where Intra-Cellular Therapies (NASDAQ:ITCI) stands against the other ...

Shares of Intra-Cellular Therapies ITCI rallied 14.9% on Friday after the company announced that it has entered into a settlement agreement with Sandoz SDZNY regarding the Caplyta (lumateperone ...

Shares of Intra-Cellular Therapies are surging 35% in premarket trading Monday after Johnson & Johnson said it will acquire the biopharmaceutical company for roughly $14.6 billion.

With increasing concern over mental health in last few years, the medicines like Caplyta (lumateperone) from Intra-Cellular Therapies Inc. (NASDAQ:ITCI) have been selling well. Caplyta is an ...

Fintel reports that on January 22, 2025, RBC Capital downgraded their outlook for Intra-Cellular Therapies (NasdaqGS:ITCI) from Outperform to Sector Perform. Analyst Price Forecast Suggests 17.02% ...

In a report released today, Jeffrey Hung from Morgan Stanley maintained a Hold rating on Intra-Cellular Therapies (ITCI – Research Report), ...

In recent trading, shares of Intra-Cellular Therapies Inc (Symbol: ITCI) have crossed above the average analyst 12-month target price of $101.27, changing hands for $127.19/share. When a stock ...